How to optimize treatment in G1 naive patients?

Anca Streinu-Cercel MD PhD

National Institute for Infectious Diseases "Prof. Dr. Matei Bals" Lecturer Carol Davila Medicine and Pharmacy University Bucharest, Romania

Diagnosis

- A 57-year old male patient naive to treatment
- First diagnose CHC in 2005 but choose to ignore VHC Ab positive
- Now remarried for the 6th time and preparing for in-vivo fertilization
- Not sure he wants treatment ?!
- HCV genotype: 1b
- HCV RNA: 7.9 log10 IU/mL
- Fibromax: F2, A3, NASH N2, ASH H0






Would you offer treatment to this patient ?

- A: Yes, why not !?
- B: Defer treatment wait for IFN free treatment
- C: Start Peg and Riba

Higher chances of cure in mild liver disease



- Higher SVR rates in milder disease stage
- Viral eradication is the only way to prevent disease progression
- Unpredictability of fibrosis progression in the presence of co-morbidities


Our patient has

- Comorbidites: Heart problems: HTA, Obesity, alter insulin tolerance...
- Concomitent medication
- DDI



Importance of Early Treatment: Increasing Prevalence of HCV and Associated Co-morbidities

- The prevalence of HCV and associated co-morbidities is increasing
 - In one cohort, the number of individuals with HCV was 17,261 in 1996 compared with 106,242 in 2006





Recommendations

- All treatment-naïve and -experienced patients with compensated disease due to HCV should be considered for therapy (Recommendation A1)
- Treatment should be prioritized for patients with significant fibrosis (METAVIR score F3 to F4) (Recommendation A1)
- Treatment is justified in patients with moderate fibrosis (METAVIR score F2) (Recommendation A2)
- In patients with no or mild disease (METAVIR score F0-F1), the indication for and timing of therapy can be individualized (Recommendation B1)
- Patients with decompensated cirrhosis who are on the transplant list should be considered for IFN-free, ideally ribavirin-free therapy (Recommendation A1)

DAA-FibroTest EASL Ref. > く企 GuideLines Version EASL - April 2014 Patient Gender Male **Fibrosis Stage** F2 **Treatment Experience** Naive **HCV Viral Load** <800.000 UI/ml **IFN** Intolerant No IFN Therapy Treatment should be

prioritized for patients with significant fibrosis (METAVIR score F3 to F4)

A2

For our patient according to the EASL guidelines 2014

➢ 6 treatment options: ✓ 3 IFN ✓ 3 IFN free



Side Effects of IFN Treatment

- Flu-like symptoms
 - Headache
 - <u>Fatigue or asthenia</u>
 - Myalgia, arthralgia
 - Fever, chills
- Nausea
- Anorexia
- Diarrhoea
- Psychiatric symptoms
 - <u>Depression</u>
 - Insomnia

- Alopecia
- Injection-site reaction
- Leucopenia
- Thyroiditis
- Autoimmunity
- Thrombocytopenia



Side Effects of RBV Treatment

- Haemolytic anaemia
- Teratogenicity
- Cough and dyspnoea
- Rash and pruritus
- Insomnia
- Anorexia



Our patient 57 years old

- HCV genotype: 1b
- HCV RNA: 7.9 log10 IU/mL
- Fibromax: F2, A3, NASH N2, ASH H0
- II28B CC
- Resistance test



DEC 2014


NS3 region (w.r.t.D90208) D30E,V35MV,V48I,Y56F,P86Q,M94L,V114I,R117C,I1 32V, V150A,I170V

NS3 region (w.r.t.H77) A7S,135MV,742S,Y56F,T61S,R62K,I64L,S68G,V71I, Q89P,S91A,R117C,I132V,A147S,L153I,I170V,N174S

	F2 n7	NS?	NS3 4A NS4B N	IS5A NS5B
drug	prediction		Scored mutations	Fold change
boceprevir	Mutation on scored position		36V, 117C, 170V	-
telaprevir	Posssible resistent		36V, 117C, 132V, 170V	1.8
simeprevir	susceptible		none	-

Resistance test provided by the National Institute of Infectious Diseases Matei Bals Bucharest

Resistant variants are present before treatment



HCV is present as a mixture of populations of genetically distinct, but closely related, virions in every patient

- 1012 virions produced per day
- 1 nucleotide mutation produced per virus produced
- All possible single nucleotide mutant virus, and all combinations of duble nucleotide mutant viruses, are though to preexist before treatment in most patients2

Most resistant variant are relatively unfit and are undetectable prior to therapy

1. Pawlotsky JM. *Clin Liver Dis*, 2003; 7:45-66; 2. Rong L. *Sci Transi Med*, 2010: 2 (30):30ra32; 3. Kuntzen: *Hepatology*, 2008; 48(6): 1769-78; 4. Bartels DJ. *J I nfec Dis*, 2008; 198: 797-9



Potent antiviral therapy eliminates sensitive variants

Antiviral

FCHR-HCV DrAG 9/21/2011



Resistant virus

Resistant variants are uncovered which can then expand




Sensitive virus

www.hivforum.org

Resistant variants can be selected during treatment





Before treatment

Time on treatment


Patients have viral variants with different levels of resistance to a drug

9/21/2011 FCHR-HCV DrAG




Resistant virus





www.hivforum.org






Explanations

Patients infected with HCV genotype 1 can be treated with a combination of weekly pegylated IFN-α, daily weight-based ribavirin 1200 mg, and daily sofosbuvir (400 mg) 12 weeks

A1



administered 12 weeks in combination with pegylated IFN-α and ribavirin. Pegylated IFN-α and ribavirin should then be administered alone for an additional 12 weeks (total treatment duration 24 weeks) in treatment-naive and prior relapser patients, including cirrhotics, and for an additional 36 weeks (total treatment duration 48 weeks) in prior partial and null responders, including cirrhotics

B1

A2


HCV RNA levels should be monitored on treatment. Treatment should be stopped if HCV RNA level is

DAA-FibroTest EASL Ref. > く 🟠 Genotype 1, Option 3 Treat for 24 weeks PEG IFN- α + ribavirin + daclatasvir **PEG IFN-A** 24 weeks PEG IFN-a weeklv **RIBAVIRIN** 24 weeks ribavirin 1200 mg DACLATASVIR 12 or 24 weeks daclatasvir 60 mg **Explanations** Patients infected with HCV genotype 1, subtype 1b can be treated with a combination of weekly B1 pegylated IFN-a, daily weight-based ribavirin 1200 mg, and daily daclatasvir (60 mg) 24 weeks

This combination should not be proposed to patients infected with HCV genotype 1, subtype 1a, given the preliminary data available, pending results of on-going large-scale studies

B1

Daclatasvir should be administered 12 weeks in combination with pegylated JEN-g and ribavirin



DAA-FibroTest EASL DAA-FibroTest EASL Ref. Genotype 1, Option 5 Genotype 1, Option 6 Treat for 12 weeks Treat for 12 weeks sofosbuvir + daclatasvir SIMEPREVIR SOFOSBUVIR 12 weeks simeprevir 150 mg sofosbuvir 400 mg SOFOSBUVIR DACLATASVIR 12 weeks sofosbuvir 400 mg daclatasvir 60 mg **Explanations Explanations** Patients infected with HCV Patients infected with HCV genotype 1 can be treated genotype 1 can be treated with an interferon-free with an interferon-free combination of daily B1 combination of daily sofosbuvir (400 mg) and sofosbuvir (400 mg) and daily daclatasvir (60 mg) 12 daily simeprevir (150 mg) for weeks in treatment-naive 12 weeks (pending data with 12 weeks of therapy in treatment-Preliminary results do not experienced patients) indicate a major advantage of adding ribavirin to this Preliminary results do not regimen. However, adding indicate a major advantage to adding ribavirin to this daily weight-based ribavirin regimen. However, adding (1000 or 1200 mg in patients daily weight-based ribavirin <75 kg or ≥ 75 kg, (1000 or 1200 mg in patients B1 respectively) should be <75 kg or ≥ 75 kg, considered in patients with respectively) should be considered in patients with predictors of poor response predictors of poor response to anti-HCV therapy, to anti-HCV therapy, especially prior nonespecially prior nonresponders and/or patients responders and/or patients

with cirrhosis

B1

with cirrhosis

Ref.

12 weeks

12 weeks



DAA-FibroTest EASL く 습 Ref. Genotype 1, Option 5 Treat for 12 weeks SIMEPREVIR 12 weeks simeprevir 150 mg SOFOSBUVIR 12 weeks sofosbuvir 400 ma **Explanations** Preliminary results do not indicate a major advantage of adding ribavirin to this regimen. However, adding daily weight-based ribavirin (1000 or 1200 mg in patients <75 kg or ≥ 75 kg, B1 respectively) should be considered in patients with predictors of poor response

to anti-HCV therapy,

especially prior non-

with cirrhosis

responders and/or patients

Genotype 1, Option 6 Treat for 12 weeks sofosbuvir + daclatasvir SOFOSBUVIR sofosbuvir 400 mg 12 weeks DACLATASVIR daclatasvir 60 mg Explanations (pending data with 12 weeks of therapy in treatmentexperienced patients)

DAA-FibroTest EASL

Ref. >

B1


Preliminary results do not indicate a major advantage to adding ribavirin to this regimen. However, adding daily weight-based ribavirin (1000 or 1200 mg in patients <75 kg or ≥75 kg, respectively) should be considered in patients with predictors of poor response to anti-HCV therapy, especially prior nonresponders and/or patients with cirrhosis








Resistant variants can be eliminated with a combination drug regimen





Patients with protease inhibitor-resistant variants can respond to Peg-IFNa/RBV




www.hivforum.org



Patients with naturally occurring polymerase inhibitor-resistant variants can respond to protease inhibitor + Peg-IFNa/RBV

Target	Variant	NS3 Linea		NS5A inhibitor	NS5B nucleoside	NS5B Palm	NS5B Thumb	NS5B Finger	Peg- IFN	RBV
NS5B	R422K	S	S	S	S	S	R	S	ß	ß
NSJD	M423T	S	S	S	S	S	R	S	S	S



AASLD/IDSA/IAS-USA 2014 HCV Treatment Recommendations Initial Therapy for Patients with Genotype 1 Chronic HCV

Patients with GT 1 HCV: Initial Treatment & Retreatment of Relapsers*

Not Recommended


Peginterferon + Ribavirin +/- [Boceprevir or Telaprevir]

Monotherapy with Peginterferon, Ribavirin, or a Direct Acting Antiviral Agent

Treatment of Decompensated Cirrhosis with Peginterferon or Simeprevir

*Patients who experienced relapse after Peginterferon plus Ribavirin therapy


DAA Agents Overview



Deliobuvir, Dasabuvir, BMS-791325

Sofosbuvir

ION 1, 2, and 3: Sofosbuvir/Ledipasvir ± RBV in Tx-Naive Pts and Previous Failures



- ✤ 8 wks adequate for noncirrhotic treatment-naive pts
- + RBV provides no benefit
- No SOF resistance observed; most virologic failures have LDV resistance

1. Afdhal N, et al. N Engl J Med. 2014;370:1889-1898. 2. Afdhal N, et al. N Engl J Med. 2014;370:1483-1493. 3. Kowdley KV, et al. N Engl J Med. 2014;370:1879-1888.

Sofosbuvir/Ledipasvir: FDA-Approved Indication

Population	Recommended Treatment Duration	
Treatment naive with or without cirrhosis	12 wks*	
Treatment experienced† without cirrhosis	12 wks	
Treatment experienced† with cirrhosis	24 wks	

*8-wk duration can be considered in treatment-naive pts without cirrhosis who have pretreatment HCV RNA < 6 million IU/mL.


Treatment-experienced pts who have failed treatment with pegIFN/RBV ± HCV PI.

Sofosbuvir/ledipasvir [package insert]. October 2014.

3 Direct Acting Antiviral Regimen

- The 3D regimen includes:
 - Co-formulated ABT-450/r/Ombitasvir with Dasabuvir
 - ABT-450, a NS3/4A protease inhibitor (identified by AbbVie and Enanta)
 - Ritonavir (pharmacokinetic enhancer)
 - Ombitasvir (ABT-267), a NS5A inhibitor
 - Dasabuvir (ABT-333), a non-nucleoside NS5B polymerase inhibitor

3D regimen in HCV genotype 1a and 1b with or without ribavirin



Andreone P, et al. DDW 2014. Abstract 929e. Ferenci et al, CROI, 2014. Press release.

Novel HCV Treatment Regimens in HCV Phase III Completed

- Sofosbuvir/Ledipasvir ± RBV
- ABT450/r + Ombitasvir + Dasabuvir ± RBV
- Daclatasvir + Asunaprevir-1b
- Phase III in progress
- Daclatasvir + Asunaprevir plus BMS-791325
- MK-5172 + MK8742

Interferon "Back bone" of HCV Therapy




Oral Therapy



Adherence Affected by Regimen Complexity and Pill Burden

- Data from HIV field illustrates virologic suppression as a function of daily pill burden[1]
- HCV triple therapy involves multiple daily pills plus injection drug
 - BOC TID: 12 pills/day
 - TVR TID: 6 pills/day
 - RBV BID: 4-6 pills/day
 - PegIFN: injection QW



Pill Burden in HCV Therapy

Fixed Dose Combination

- 1) Ledipasvir/Sofosbuvir
- 2) MK-5172 and MK-5842-potentially

3 DAA Regimens

450r/Ombitasvir +Dasabuvir



- Simeprevir plus Sofosbuvir
- Daclatasvir (when approved) and Sofosbuvir
- Asunaprevir+ Daclatasvir+BMS-791325





Ribavirin 2-6 pills a day


Motivating Pts to Complete HCV Treatment

- Future HCV-related health problems most important factor encouraging therapy initiation
 - HCV therapy efficacy and safety also significant
- Fear of adverse events most important factor limiting initiation and completion of HCV therapy
- Pt fears can be overcome with open communication and education
- Emotional support (family, friends, support groups) important motivators for treatment initiation and adherence

Summary: Adherence Support Strategies

- Pill burden, regimen complexity, AEs adversely effect adherence
- Common strategies for adherence support
 - Pt education
 - Scheduling alarms (eg, cell phone)
 - Pill boxes/organizers
 - Blister packs
 - Medication worksheets

And for second concern check DDI...



And ..





La maladie hépatique est sévère

PBH antérieure F3 ou F4	
Ou Fibroscan ≥ 9,5 kPa	Traitement à court terme
Ou FibroTest ≥ 0,59	Traitement à court terme
Ou FibroMètre ≥ 0,63	

Le bénéfice clinique à traiter rapidement le malade est important : diminution du risque de décompensation de la maladie hépatique, diminution du risque de carcinome hépatocellulaire, amélioration de la survie.

La maladie hépatique est peu sévère

Fibroscan < 5,6 kPa	Surveillance annuelle. Le traitement à court		
ou FibroTest < 0,27			
ou FibroMètre < 0,33	terme n'est pas nécessaire.		

Le bénéfice clinique à traiter le malade dans l'année qui vient n'est pas montré. Cependant, une surveillance annuelle par l'une de ces méthodes est recommandée.

www.afef.asso.fr




La maladie hépatique est difficile à évaluer

Fibroscan 5,6 – 9,4 kPa ou FibroTest 0,27 – 0,58 ou FibroMètre 0,33 – 0,62	Faire un deuxième test		
Lorsque deux méthodes sont utilisées succes l'élasticité hépatique à un test sanguin (et non deu	sivement, il convient d'associer une mesure de ix tests sanguins).		
Fibroscan 5,6 – 9,4 kPa et Fibrotest ≥ 0,59 ou Fibroscan 5,6 – 9,4 kPa et Fibromètre ≥ 0,63	La maladie hépatique est sévère		
FibroTest 0,27 – 0,58 et Fibroscan ≥ 9,5 kPa ou Fibromètre 0,33 – 0,62 et Fibroscan ≥ 9,5 kPa	Traitement à court terme		
Fibroscan < 7,1 kPa et Fibrotest < 0,48 ou Fibroscan < 7,1 kPa et Fibromètre < 0,41	La maladie hépatique est peu sévère. Surveillance annuelle. Le traitement à court terme n'est pas nécessaire.		
Dans les autres cas	Surveillance à un an et envisager un traitement à moyen terme (2 à 3 ans)		

www.afef.asso.fr


Study Design

- Sofosbuvir (nucleotide NS5B inhibitor) 400 mg / ledipasvir (NS5A inhibitor) 90 mg once daily
- GS-9669 (non-nucleoside NS5B inhibitor) 500 mg once daily
- GS-9451 (a protease/ NS3/4 inhibitor) 80 mg once daily




Treatment Response (ITT)

- Sofosbuvir + Ledipasvir (n=20)
- Sofosbuvir + Ledipasvir + GS-9669 (n= 20)
- Sofosbuvir + Ledipasvir + GS-9451 (n= 20)





Impact of improving HCV treatment



Thomas DL. Lancet 2010;376:1441-1442

Wait and monitor..

